BNP Paribas Financial Markets’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

BNP Paribas Financial Markets’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,246	Closed	-$72	–	4574
2019 Q4	$72	Sell	2,246 -29	-1%	-$6	﹤0.01%	4344
2019 Q3	$455	Hold	2,275	–	–	﹤0.01%	4425
2019 Q2	$1.98K	Sell	2,275 -973	-30%	-$1.52K	﹤0.01%	4321
2019 Q1	$7.54K	Buy	+3,248	New	+$8.8K	﹤0.01%	4048
2018 Q4	–	Sell	-567	Closed	-$8.4K	–	4495
2018 Q3	$8.4K	Hold	567	–	–	﹤0.01%	3816
2018 Q2	$8.61K	Sell	567 -2,350	-81%	-$39.9K	﹤0.01%	3852
2018 Q1	$54.8K	Buy	2,917 +1,780	+157%	+$31.1K	﹤0.01%	3516
2017 Q4	$20.6K	Buy	+1,137	New	+$24K	﹤0.01%	3960

BNP Paribas Financial Markets's SNNA Position: Q1 2020 in Review

BNP Paribas Financial Markets sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2020, closing a stake of 2,246 shares — an estimated $72 sold.

BNP Paribas Financial Markets first reported a position in SNNA in Q4 2017 and held it in 8 quarters. The position peaked at $54.8K in Q1 2018. 1 fund tracked by Wall St. Rank holds SNNA as of Q1 2020.

BNP Paribas Financial Markets reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
BNP Paribas Financial Markets sold 2,246 Sienna Biopharmaceuticals, Inc. shares in Q1 2020, an estimated $72.
BNP Paribas Financial Markets first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
BNP Paribas Financial Markets's Sienna Biopharmaceuticals, Inc. position peaked at $54.8K in Q1 2018.
1 fund tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2020.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2020, filed 13 May 2020.